Pubblicazioni

Autori:

Gisondi, Paolo; Geat, Davide; Conti, Andrea; Dapavo, Paolo; Piaserico, Stefano; De Simone, Clara; Bianchi, Luca; Costanzo, Antonio; Malagoli, Piergiorgio; Malara, Giovanna; Micali, Giuseppe; Naldi, Luigi; Offidani, Annamaria; Patrizi, Annalisa; Prignano, F.; Parodi, Aurora; Rongioletti, Franco; Calzavara-Pinton, Piergiacomo; Girolomoni, Giampiero

Titolo:

TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis

Anno:

2020

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

A Stampa

Referee:

Sì

Nome rivista:

EXPERT REVIEW OF CLINICAL IMMUNOLOGY

ISSN Rivista:

1744-666X

N° Volume:

16

Numero o Fascicolo:

6

Intervallo pagine:

591-598

Parole chiave:

Biosimilars; biologics; plaque psoriasis; psoriasis; TNF-α inhibitors

Breve descrizione dei contenuti:

Introduction: Biologics have revolutionized the therapy of moderate-to-severe plaque psoriasis. Despite their greater efficacy over conventional systemic therapies their high cost has represented a burden for health-care systems, which limited their use. The availability of biosimilars at low cost is changing the place in therapy of biologics for psoriasis. Areas covered: The role of TNF- α inhibitors in the management of plaque psoriasis, their efficacy and safety profile are presented. Phase 3 clinical trials and real-life data from the use of TNF- α inhibitor biosimilars in the treatment of plaque psoriasis are also reviewed in detail. Furthermore, arguments in favor of the use of TNF- α inhibitor biosimilars as a first-line therapy in moderate-to-severe plaque psoriasis are discussed. Expert opinion: An increasing amount of data show that biosimilars represent a safe and effective alternative to the originator biologics. In the face of ever-increasing health-care costs, switching to biosimilars and starting naïve patients on the best-value biologic can reduce expenditure for patients and payers while maintaining a high-quality care. Moreover, as the cost of biosimilars is approaching the cost of conventional systemic treatments, TNF-α inhibitors biosimilars may represent a first-line systemic treatment for psoriasis patients because they are effective and safe.

Id prodotto:

115589

Handle IRIS:

11562/1022115

ultima modifica:

30 ottobre 2024

Citazione bibliografica:

Gisondi, Paolo; Geat, Davide; Conti, Andrea; Dapavo, Paolo; Piaserico, Stefano; De Simone, Clara; Bianchi, Luca; Costanzo, Antonio; Malagoli, Piergiorgio; Malara, Giovanna; Micali, Giuseppe; Naldi, Luigi; Offidani, Annamaria; Patrizi, Annalisa; Prignano, F.; Parodi, Aurora; Rongioletti, Franco; Calzavara-Pinton, Piergiacomo; Girolomoni, Giampiero, TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis «EXPERT REVIEW OF CLINICAL IMMUNOLOGY» , vol. 16 , n. 6 , 2020 , pp. 591-598

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo